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LETTER TO THE EDITOR

Osteonecrosis of the jaw from bone anti-resorptives:
impact of skeletal site-dependent mesenchymal stem cells
Dear Editor,
Recently, two Letters to the Editor addressed the use of
bone mesenchymal (Gonzalvez-Garcia et al, 2012) and
hematopoietic (Elad et al, 2012) stem cells in the management of osteonecrosis of the jaw (ONJ), a common complication of bone anti-resorptive therapies. Clearly,
bisphosphonates and denosumab are highly efﬁcacious in
controlling dysregulated bone remodeling in osteoporosis,
Paget’s disease, multiple myeloma, and skeletal events of
cancer metastasis; however, ONJ is still an unpredictable
recalcitrant oral complication (Stopeck et al, 2010; Fusco
et al, 2011). The underlying pathophysiological mechanism
of ONJ is still unclear, so prevention of ONJ is challenging.
Also, there is a paucity of randomized controlled clinical trials on ONJ therapies, so management algorithms are still
empirical (Montebugnoli et al, 2007; Stockmann et al,
2010; Moretti et al, 2011). Both bisphosphonates and denosumab directly inhibit osteoclasts, but bisphosphonates inhibit osteoclastic activity also indirectly through osteoblasts
and bone mesenchymal stem cells (BMSCs) both of which
express the cell surface ‘receptor activator of NFjB ligand’
(RANKL) known to interact with RANK on osteoclast precursors (Nishida et al, 2005; Roelofs et al, 2006). As
BMSCs can differentiate into multiple cell types including
pre-osteoblasts and osteoblasts, some investigators have
successfully transplanted BMSCs to treat ONJ both clinically and in animal studies (Kikuiri et al, 2010; Cella et al,
2011; Li et al, 2013). The function of BMSCs in these studies, although attributed to immune modulation, does not
explain the jaw-speciﬁc character of ONJ.
Osteonecrosis of the jaw, induced by bone anti-resorptives, speciﬁcally targets the jaw unlike other forms of
osteonecrosis in response to irradiation (osteoradionecrosis),
infection (osteomyelitis), corticosteroid therapy (steroidinduced osteonecrosis), and alcoholism (alcohol-induced
osteonecrosis) which can develop in non-oral skeletal sites
(Akintoye and Hersh, 2012). It is still unclear why ONJ
targets orofacial bones, so the successful use of BMSC
transplants to treat ONJ draws attention to possible roles of
jaw-speciﬁc characteristics of orofacial BMSCs (OFMSCs)
in ONJ pathogenesis and its preference for oral bone. It has
been shown that BMSCs are phenotypically and functionally site speciﬁc in terms of their survival, differentiation,
and response to growth factors when compared with MSCs
from axial/appendicular bones (Akintoye et al, 2006; Aghaloo et al, 2010). Moreover, OFMSCs are more responsive
to bisphosphonate and irradiation relative to non-oral
BMSCs (Stefanik et al, 2008; Damek-Poprawa et al,
2010). These jaw-speciﬁc characteristics of OFMSCs could
shed some light on the preferential jaw localization of
ONJ as well as high incidence of jaw osteoradionecrosis

following head and neck cancer radiotherapy (Stefanik
et al, 2008; Damek-Poprawa et al, 2010). Osteogenic differentiation and osteoclast recruiting abilities of BMSCs are
necessary for bone homeostasis and repair; therefore, it is
possible that anti-resorptives such as bisphosphonate and
denosumab apparently uncouple osteoblast–osteoclast balance in a skeletal site-speciﬁc pattern to favor the onset of
ONJ. The elusiveness of mechanisms that underlie the
jaw-speciﬁc nature of ONJ has made prevention and complete cure of ONJ challenging without invasive surgery.
Further understanding of OFMSC functions and cellular
interactions in ONJ could shed more light on its pathogenesis and promote the development of potential preventive
therapies.
SO Akintoye
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